Baumgarten C R, Nichols R C, Naclerio R M, Lichtenstein L M, Norman P S, Proud D
J Immunol. 1986 Aug 1;137(3):977-82.
We have shown recently that kinins are generated during experimentally induced allergic rhinitis in man, and have demonstrated that substrates for kinin-forming enzymes are provided during the allergic response by a transudation of kininogens from plasma into nasal secretions. In light of this increased vascular permeability during the allergic reaction, we have extended our studies on the mechanisms of kinin formation to examine the potential involvement of plasma kallikrein. Allergic individuals (n = 7) and nonallergic controls (n = 7) were challenged intranasally with an allergen, and nasal lavages, obtained before and after challenge, were assayed for immunoreactive human plasma kallikrein/prekallikrein (iHPK). Post-challenge iHPK values were significantly elevated (p less than 0.01) in the allergic group (353 +/- 394 ng/ml; x +/- SD) as compared to the nonallergics (19 +/- 22 ng/ml), and correlated with increases in kinins, histamine, and N-alpha-tosyl-L-arginine methyl esterase (TAME-esterase) activity and with the onset of clinical symptoms. Gel filtration studies revealed that plasma prekallikrein is activated during the allergic response and contributes to kinin formation prior to interaction with plasma protease inhibitors. We also show that the majority of the TAME-esterase activity detected in nasal secretions during the allergic response is due to activities consistent with a plasma kallikrein/alpha 2-macroglobulin complex and with mast cell tryptase.
我们最近已表明,在人体实验性变应性鼻炎期间会生成激肽,并且已证实,在变应性反应过程中,激肽原通过从血浆渗出至鼻分泌物中,为激肽形成酶提供了底物。鉴于变应性反应期间血管通透性增加,我们已将对激肽形成机制的研究扩展至检查血浆激肽释放酶的潜在参与情况。变应性个体(n = 7)和非变应性对照(n = 7)经鼻内给予变应原进行激发,对激发前后获得的鼻灌洗液检测免疫反应性人血浆激肽释放酶/前激肽释放酶(iHPK)。与非变应性个体(19 ± 22 ng/ml)相比,变应性组激发后iHPK值显著升高(p < 0.01)(353 ± 394 ng/ml;x ± SD),并且与激肽、组胺和N-α-甲苯磺酰-L-精氨酸甲酯酶(TAME-酯酶)活性的增加以及临床症状的出现相关。凝胶过滤研究显示,血浆前激肽释放酶在变应性反应期间被激活,并在与血浆蛋白酶抑制剂相互作用之前促进激肽形成。我们还表明,变应性反应期间在鼻分泌物中检测到的大部分TAME-酯酶活性归因于与血浆激肽释放酶/α2-巨球蛋白复合物以及肥大细胞类胰蛋白酶一致的活性。